chondroitin; glucosamine; knee osteoarthritis; symptomatic slow-acting drugs for osteoarthritis (SYSADOAs)
Abstract :
[en] The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) treatment algorithm recommends chronic symptomatic slow-acting drugs for osteoarthritis (SYSADOAs) including glucosamine sulfate (GS) and chondroitin sulfate (CS) as first-line therapy for knee osteoarthritis (OA). Numerous studies are published on the use of SYSADOAs in OA; however, the efficacy of this class is still called into question largely due to the regulatory status, labeling and availability of these medications which differ substantially across the world. Examination of the evidence for the prescription patented crystalline GS (pCGS) formulation at a dose of 1500 mg once-daily demonstrates superiority
overother GS and glucosamine hydrochloride (GH) formulations and dosage regimens. Thus, the ESCEO task force advocates differentiation of prescription pCGS over other glucosamine preparations. Long-term clinical trials andreal-life studies show that pCGS may delay joint structural changes, suggesting potential benefit beyond symptom control when used early in the management of knee OA. Real-life pharmacoeconomic studies demonstrate a long-term reduction in the need for additional pain analgesia and non-steroidal anti-inflammatory drugs (NSAIDs) with pCGS, with a significant reduction of over 50% in costs associated with medications, healthcare consultations and examinations over 12 months.
Furthermore, treatment with pCGS for at least 12 months leads to a reduction in the need for total joint replacement for at least 5 years following treatment cessation. Thus, pCGS(1500 mg od) is a logical choice to maximize clinical benefit in OA patients, with demonstrated medium-term control of pain and lasting impact on disease progression.
Disciplines :
General & internal medicine
Author, co-author :
Bruyère, Olivier ; Université de Liège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Altman, R.D.
Reginster, Jean-Yves ; Université de Liège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Language :
English
Title :
Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: Evidence from real-life setting trials and surveys.
Publication date :
2016
Journal title :
Seminars in Arthritis and Rheumatism
ISSN :
0049-0172
eISSN :
1532-866X
Publisher :
W.B. Saunders, Philadelphia, United States - Pennsylvania
Bruyere O., Cooper C., Pelletier J.P., Branco J., Brandi M.L., Guillemin F., et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum 2014, 44:253-263.
Cutolo M., Berenbaum F., Hochberg M., Punzi L., Reginster J.Y. Commentary on recent therapeutic guidelines for osteoarthritis. Semin Arthritis Rheum 2014, 44:611-617.
De Wan M, Volpi G, Inventors; Rottapharm, assignee. Method of preparing mixed glucosamine salts. USA patent 5,847,107. 1998.
Bruyere O., Cooper C., Pelletier J.-P., Maheu E., Rannou F., Branco J., et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-from evidence-based medicine to the real-life setting. Semin Arthritis Rheum 2016, 45(Suppl.):S3-S11.
Jordan K.M., Arden N.K., Doherty M., Bannwarth B., Bijlsma J.W.J., Dieppe P., et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003, 62:1145-1155.
Hochberg M.C., Altman R.D., April K.T., Benkhalti M., Guyatt G., McGowan J., et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 2012, 64:465-474.
Jevsevar D.S. Treatment of osteoarthritis of the knee: evidence-based guideline, 2nd edition. J Am Acad Orthop Surg 2013, 21:571-576.
McAlindon T.E., Bannuru R.R., Sullivan M.C., Arden N.K., Berenbaum F., Bierma-Zeinstra S.M., et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 2014, 22:363-388.
Clegg D.O., Reda D.J., Harris C.L., Klein M.A., O'Dell J.R., Hooper M.M., et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006, 354:795-808.
Hamerman D. The biology of osteoarthritis. N Engl J Med 1989, 320:1322-1330.
Rovati L.C., Girolami F., Persiani S. Crystalline glucosamine sulfate in the management of knee osteoarthritis: efficacy, safety, and pharmacokinetic properties. Ther Adv Musculoskelet Dis 2012, 4:167-180.
Reginster J.Y., Neuprez A., Lecart M.P., Sarlet N., Bruyere O. Role of glucosamine in the treatment for osteoarthritis. Rheumatol Int 2012, 32:2959-2967.
Chiusaroli R., Piepoli T., Zanelli T., Ballanti P., Lanza M., Rovati L.C., et al. Experimental pharmacology of glucosamine sulfate. Int J Rheumatol 2011, 2011:939265.
Largo R., Alvarez-Soria M.A., Diez-Ortego I., Calvo E., Sanchez-Pernaute O., Egido J., et al. Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes. Osteoarthritis Cartilage 2003, 11:290-298.
Chan P.S., Caron J.P., Rosa G.J., Orth M.W. Glucosamine and chondroitin sulfate regulate gene expression and synthesis of nitric oxide and prostaglandin E(2) in articular cartilage explants. Osteoarthritis Cartilage 2005, 13:387-394.
Taniguchi S., Ryu J., Seki M., Sumino T., Tokuhashi Y., Esumi M. Long-term oral administration of glucosamine or chondroitin sulfate reduces destruction of cartilage and up-regulation of MMP-mRNA in a model of spontaneous osteoarthritis in Hartley guinea pigs. J Orthop Res 2012, 30:673-678.
Uitterlinden E.J., Jahr H., Koevoet J.L., Jenniskens Y.M., Bierma-Zeinstra S.M., Degroot J., et al. Glucosamine decreases expression of anabolic and catabolic genes in human osteoarthritic cartilage explants. Osteoarthritis Cartilage 2006, 14:250-257.
Eriksen P., Bartels E.M., Altman R.D., Bliddal H., Juhl C., Christensen R. Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptomatic relief of osteoarthritis: a meta-analysis of placebo-controlled trials. Arthritis Care Res (Hoboken) 2014, 66:1844-1855.
Reginster J.Y. The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest. Arthritis Rheum 2007, 56:2105-2110.
Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
Herrero-Beaumont G., Ivorra J.A., Del Carmen Trabado M., Blanco F.J., Benito P., Martin-Mola E., et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum 2007, 56:555-567.
Reginster J.Y., Deroisy R., Rovati L.C., Lee R.L., Lejeune E., Bruyere O., et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001, 357:251-256.
Pavelka K., Gatterova J., Olejarova M., Machacek S., Giacovelli G., Rovati L.C. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002, 162:2113-2123.
Zhang W., Nuki G., Moskowitz R.W., Abramson S., Altman R.D., Arden N.K., et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010, 18:476-499.
Bjordal J.M., Klovning A., Ljunggren A.E., Slordal L. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: a meta-analysis of randomised placebo-controlled trials. Eur J Pain 2007, 11:125-138.
Bjordal J.M., Ljunggren A.E., Klovning A., Slordal L. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. Br Med J 2004, 329:1317.
Altman R.D., Abadie E., Avouac B., Bouvenot G., Branco J., Bruyere O., et al. Total joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis. Osteoarthritis Cartilage 2005, 13:13-19.
Hochberg M.C., Zhan M., Langenberg P. The rate of decline of joint space width in patients with osteoarthritis of the knee: a systematic review and meta-analysis of randomized placebo-controlled trials of chondroitin sulfate. Curr Med Res Opin 2008, 24:3029-3035.
Kahan A., Uebelhart D., De Vathaire F., Delmas P.D., Reginster J.Y. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009, 60:524-533.
Wildi L.M., Raynauld J.P., Martel-Pelletier J., Beaulieu A., Bessette L., Morin F., et al. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Ann Rheum Dis 2011, 70:982-989.
Zegels B., Crozes P., Uebelhart D., Bruyere O., Reginster J.Y. Equivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study. Osteoarthritis Cartilage 2013, 21:22-27.
Hochberg M.C., Martel-Pelletier J., Monfort J., Moller I., Castillo J.R., Arden N., et al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis 2016, 75:37-44. 10.1136/annrheumdis-2014-206792.
Martel-Pelletier J., Roubille C., Abram F., Hochberg M.C., Dorais M., Delorme P., et al. First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: data from the osteoarthritis initiative progression cohort. Ann Rheum Dis 2015, 74:547-556.
Fransen M., Agaliotis M., Nairn L., Votrubec M., Bridgett L., Su S., et al. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis 2015, 74:851-858.
Bruyere O., Pavelka K., Rovati L.C., Gatterova J., Giacovelli G., Olejarova M., et al. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthritis Cartilage 2008, 16:254-260.
Raynauld J.P., Martel-Pelletier J., Haraoui B., Choquette D., Dorais M., Wildi L.M., et al. Risk factors predictive of joint replacement in a 2-year multicentre clinical trial in knee osteoarthritis using MRI: results from over 6 years of observation. Ann Rheum Dis 2011, 70:1382-1388.
Rovati L.C., Girolami F., D'Amato M., Giacovelli G. Effects of glucosamine sulfate on the use of rescue non-steroidal anti-inflammatory drugs in knee osteoarthritis: results from the Pharmaco-Epidemiology of GonArthroSis (PEGASus) study. Semin Arthritis Rheum 2016, 45(Suppl.):S34-S41.
Persiani S., Roda E., Rovati L.C., Locatelli M., Giacovelli G., Roda A. Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthritis Cartilage 2005, 13:1041-1049.
Jackson C.G., Plaas A.H., Sandy J.D., Hua C., Kim-Rolands S., Barnhill J.G., et al. The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination. Osteoarthritis Cartilage 2010, 18:297-302.
Persiani S., Rotini R., Trisolino G., Rovati L.C., Locatelli M., Paganini D., et al. Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose. Osteoarthritis Cartilage 2007, 15:764-772.
Russell A.S., Aghazadeh-Habashi A., Jamali F. Active ingredient consistency of commercially available glucosamine sulfate products. J Rheumatol 2002, 29:2407-2409.
Scholtissen S., Bruyere O., Neuprez A., Severens J.L., Herrero-Beaumont G., Rovati L., et al. Glucosamine sulphate in the treatment of knee osteoarthritis: cost-effectiveness comparison with paracetamol. Int J Clin Pract 2010, 64:756-762.
Black C., Clar C., Henderson R., MacEachern C., McNamee P., Quayyum Z., et al. The clinical effectiveness of glucosamine and chondroitin supplements in slowing or arresting progression of osteoarthritis of the knee: a systematic review and economic evaluation. Health Technol Assess 2009, 13:1-148.
